Understanding physician–pharmaceutical industry interactions

Understanding Physician-Pharmaceutical Industry Interactions

Volumn , Issue , 2007, Pages 1-141

  Jain, Shaili ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925217769     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511665677     Document Type: Book

References (182)

1. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346(7): 498-505
2. Sigworth SK, Nettleman MD, Cohen GM. Pharmaceutical branding of resident physicians. JAMA 2001; 286(9) 1024-5.
3. Katz D, Mansfield P, Goodman R, Tiefer L, Merz J. Psychological aspects of gifts from drug companies. JAMA 2003; 290(18)2404-5.
4. Rhodes R, Capozzi JD. The invisible influence of industry inducements. Am J Bioethics 2003; 3(3)65-7
5. Lo B. Resolving Ethical Dilemmas: A Guide for Clinicians. Williams & Wilkins, Baltimore, 1995
6. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA 2001; 285(15)2009-12.
7. Stahl S. It takes two to entangle: Separating medical education from pharmaceutical promotion. Psychopharmacology Educational Update. 2005 (March):1, 6.
8. Goodwin FK. Safe and effective drugs have improved the lives of millions. Psychol Today 1999; 32(5)40-2
9. Desmet C. Pharmaceuticals firms’ generosity and physicians: Legal aspects in Belgium. Med Law 2003; 22(3)473-87.
10. Spilker B. The benefits and risks of a packet of M&M's. Health Aff2002; 21(2):243-4
11. Peppin JF. Pharmaceutical sales representatives and physicians: Ethical considerations of a relationship. J Med Philos 1996; 21(1):83-99.
12. Williams, S.C. Food for thought. Why physicians should reconsider gifts from pharmaceutical companies. Curr Surg 2003; 60(2)152-3.
13. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 2000; 283(3)373-80.
14. Jonsen AR. Ethics of drug giving and drug taking. Drug Issues 1988; 18(2):195-200
15. Brody H. The company we keep: Why physicians should refuse to see pharmaceutical representatives. Ann Fam Med 2005; 3(1):82-5.
16. Lo B. Resolving Ethical Dilemmas: A Guide for Clinicians. Williams & Wilkins, Baltimore, 1995
17. Blake RL, Early EK. Patients’ attitudes about gifts to physicians from pharmaceutical companies. J Am Board Fam Pract 1995; 8(6)1457-64.
18. Goldrich MS. Psychological aspects of gifts from drug companies. JAMA 2003; 290(18)2405
19. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA; 290(2)252-5.
20. Gibbons RV, Landry FJ, Blouch DL, Jones DL, Williams FK, Lucey CR, Kroenke K. A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998; 13(3): 151-4.
21. Steinman MA, Shilipak MG, McPhee SJ. Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001; 110(7):551-7.
22. Gudmundsson S. Doctors and drug companies: The beauty and the beast. Acta Ophthalmol Scand 2005; 83:407-8
23. Barton L. Ethics, profit and patients. When pharmaceutical companies sponsor medical meetings. J Hosp Mark 1993; 8(1)171-82.
24. Gaedeke RM, Tootlelian DH, Sanders EE. Value of services provided by pharmaceutical companies: Perceptions of physicians and pharmaceutical sales representatives. Health Mark Q 1999; 17(1):23-31.
25. Ferguson RP. Need for better interactions between physicians and pharmaceutical sales representatives. Ann Pharmacother 2002; 36(12): 1966-8
26. Ferguson RP, Rhim E, Belizaire W, Egede L, Carter K, Larsdale T. Encounters with pharmaceutical sales representatives among practicing internists. Am J Med 1999; 107(2):149-52
27. Ma J, Stafford RS, Cockburn IM, Finkelstein SN. A statistical analysis of the magnitude and composition of drug promotion in the US in 1998. Clin Ther 2003; 25(5): 1503-17
28. Manchanda P, Honka E. The effects and role of direct to physician marketing in the pharmaceutical industry: An integrative review. Yale J Health Policy Law Ethics 2005; 5(2)785-822
29. Spiller LD, Wymer WW. Physicians’ perceptions and uses of commercial drug information sources: An examination of pharmaceutical marketing to physicians. Health Mark Q 2001; 19(1):91-106.
30. Greene JA. Attention to “details”: Etiquette and the pharmaceutical salesman in postwar America. Soc Stud Sci 2004; 34(2)271- 92.
31. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000; 283(3)373-80
32. Ferguson RP. Training the resident to meet the detail men. JAMA 2000; 283(3): 373-80.
33. Franko JP, Shaughnessey AF, Slawson DC. Obtaining useful information from pharmaceutical company representatives. In: Information Mastery: Evidence Based Family Medicine, 2nd ed. (WW Rosser, DC Slawson and AF Shaughnessy, Eds.). BC Decker, 2004.
34. Levinson W, Dunn PM. Counterdetailing. JAMA 1984; 251(16): 2084.
35. Siegel D, Lopez J, Meier J, Goldstein MK, Lee S, Brazill BJ, Matalka MS. Academic detailing to improve antihypertensive prescribing patterns. Am J Hypertens 2003; 16(6):508-11
36. Denton GD, Smith J, Faust J, Holmboe E. Comparing the efficacy of staff versus housestaff instruction in an intervention to improve hypertension management. Acad Med 2001; 76(12): 1257-60.
37. Moser SE, Dorsch JN, Kellerman R. The RAFT approach to academic detailing with preceptors. Fam Med 2004; 36(5)1316-18
38. Johns MM, Barnes M, Florencio PS. Restoring balance to industry-academia relationships in an era of institutional financial conflicts of interest: Promoting research while maintaining trust. JAMA 2003; 289(6):741-6
39. Brodkey AC. The role of the pharmaceutical industry in teaching psychopharmacology: A growing problem. Acad Psychiatry 2005; 29(2)1222-9.
40. Boyd EA, Bero LA. Assessing faculty financial relationships with industry: A case study. JAMA 2000; 284(17)2209-14
41. Angell M. Is academic medicine for sale?N Engl J Med 2000; 342(20): 1516-18
42. Davidoff F. Between the lines: Navigating the uncharted territory of industry-sponsored research. Health Aff (Millwood) 2002; 21(2)235-42.
43. Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, et al. Sponsorship, authorship, and accountability. Lancet 2001; 358:854–6.
44. Wright IC. Conflict of interest and the British Journal of Psychiatry. Br J Psychiatry 2002; 180:82-3
45. Just how tainted has medicine become? [Editorial]. Lancet 2002; 359: 1167–8.
46. Lagnado M. Increasing the trust in scientific authorship. Br J Psychiatry 2002; 359:1167–8.
47. Bodenheimer T. Uneasy alliance - clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342(20)539-44.
48. Rae-Grant, O. Challenges of the pharmaceutical-physician boundary. Can J Psychiatry 2003; 48(5)287-8
49. Healy D, Cattell D. Interface between authorship: Industry and science in the domain of therapeutics. Br J Psychiatry 2003; 183:22-7.
50. Krimsky S, Rothenberg LS, Stott P, Kyle G. Scientific journals and their authors’ financial interests. Psychother Psychosom 1998; 67(4-5): 194-201
51. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA2002; 287(5):612-17
52. Smith R. Medical journals and pharmaceutical companies: Uneasy bedfellows. BMJ 2003: 326(7400): 1202-5
53. Ashar BH, Miller RG, Getz KJ, Powe NR. Prevalence and determinants of physician participation in conducting pharmaceutical-sponsored clinical trials and lectures. J Gen Intern Med 2004; 19(11):1140–5
54. Warner TD, Roberts LW. Scientific integrity; fidelity and conflicts of interest in research. Curr Opin Psychiatry 2004; 17:381-5.
55. Mirowski P, Van Horn R. The contract research organization and the commercialization of scientific research. Soc Stud Sci 2005; 35(4)503-48
56. Puttagunta PS, Caulfield TA, Griener G. Conflict of interest in clinical research. Health Law Rev 2002; 10(2)30-2
57. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002; 190(9): 583–92.
58. Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003; 183: 498-506
59. Melander H, Ahlquist-Rastad J, Meijer G, Beerman B. Evidence b(1)ased medicine. BMJ 2003: 326(7400): 1171-3
60. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ2003; 326(7400): 1167-70
61. Rennie D. Fair conduct and fair reporting of clinical trials. JAMA 1999; 282(18): 1766-8
62. Steinbrook R. Registration of clinical trials - voluntary or mandatory? N Engl J Med 2004; 351(18) 820-2
63. Rennie D. Trial registration: A great idea switches from ignored to irresistible. JAMA 2004; 292(11): 1359-62
64. Bellin M, McCarthy S, Drevlow L, Pierach C. Medical students’ exposure to pharmaceutical industry marketing: A survey of one U.S. medical school. Acad Med 2004; 79(11): 1041-5.
65. Wazana A.Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000; 283(3) 73-80
66. Kassirer JP. Financial indigestion. JAMA 2000; 284(17):2156-7.
67. Shaughnessy AF, Slawson DC, Bennett JH. Teaching information mastery: Evaluating information provided by pharmaceutical representatives. Fam Med 1995; 27(9) 581- 5
68. American Medical Association Council on Ethical and Judicial Affairs. Opinion 8.0601: Gifts to physicians from industry. Available at: http://www.ama-assn.org/ama/pub/category/4001.html (last accessed June 2006)
69. Principles to guide the relationship between graduate medical education and industry. Available at: http://www.acgme.org (under GME information; under Position Papers; last accessed June 2006). Accreditation Council for Graduate Medical Education, 2002
70. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? Arch Intern Med 2003; 163(18):2213- 18.
71. Watkins RS, Kimberly J Jr. What residents don’t know about physician pharmaceutical industry interactions. Acad Med 2004; 79(5)432-7.
72. Monaghan MS, Galt KA, Turner PD, Houghton BL, Rich EC, Markert RJ, Bergman-Evans B. Student understanding of the relationship between the health professions and the pharmaceutical industry. Teach Learn Med 2003; 15(1): 14-20
73. Wilkes MS, Hoffman JR. An innovative approach to educating medical students about pharmaceutical promotion. Acad Med 2001 Dec; 76(12): 1271-7
74. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003; 290(2) 252-5
75. Smith S, Fryer-Edwards K, Diekema DS, Braddock CH 3rd. Finding effective strategies for teaching medical ethics: A comparison trial of two interventions. Acad Med 2004; 79(3) 265-71.
76. Hopper JA, Speece MW, Musial JL. Effects of an educational intervention on residents’ knowledge and attitudes toward interactions with pharmaceutical representatives. J Gen Intern Med 1997; 12(10):639-42.
77. Palmisano P, Edelstein J. Teaching drug promotion abuses to health profession students. J Med Educ 1980; 55(5) 1453-5.
78. Anastasio GD, Little JM Jr. Pharmaceutical marketing: Implications for medical residency training. Pharmacotherapy 1996; 16(1):103-7.
79. Agrawal S, Saluja I, Kaczorowski J. A prospective before and after trial of an educational intervention about pharmaceutical marketing. Acad Med 2004; 79(11): 1046-50
80. Levinson W, Dunn PM. Counterdetailing. JAMA 1984; 251(16)2004.
81. Siegel D, Lopez J, Meier J, Goldstein M, KLee S, Brazill BJ, Matalka MS. Academic detailing to improve antihypertensive prescribing patterns. Am J Hypertens 2003; 16(6):508-11
82. Denton GD, Smith J, Faust J, Holmboe E. Comparing the efficacy of staff versus house staff instruction in an intervention to improve hypertension management. Acad Med 2001; 76(12): 1257-60.
83. Moser SE, Dorsch JN, Kellerman R. The RAFT approach to academic detailing with preceptors. Fam Med 2004; 36(5) 1316-18.
84. Kelcher S, Brownoff R, Meadows LM. Structured approach to pharmaceutical representatives. Can Fam Physician 1998; 44:1053-60
85. Coyle SL. Physician-industry relations. Part 2: Organizational issues. Ann Intern Med 2002; 136(5) 403-6
86. Wilson FS. Continuing medical education: Ethical collaboration between sponsor and industry. Clin Orthop 2003; 412: 33-7
87. ACGME and ACCME. Joint statement regarding graduate and continuing medical education's relationship with industry. November 2004.
88. Capozzi JD, Rhodes R, Delsignore J. Medical education and corporate sponsorship. J Bone Joint Surg Am 2003; 85A(1): 168-70.
89. Packer S, Parke DW. Ethical concerns in industry support of CME. Arch Ophthalmol 2004; 122(5) 773-6
90. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA 2001; 285(15) 2009-12
91. Tenery RM Jr. Interactions between physicians and the health care technology industry. JAMA 2000; 283(3) 391-3
92. Accreditation Council for Continuing Medical Education Annual Report Data 2001. ACCME, Chicago, 2002
93. Holmer AF. Industry strongly supports continuing medical education. JAMA 2001; 285(15):2012-14
94. Chepesiuk R. Supported by an unrestricted educational grant. CMAJ 2003; 169 (5):421-2
95. Davis DA. CME and the pharmaceutical industry: Two worlds, three views, four steps. CMAJ 2004; 171(2) 149-50.
96. Katz HP, Goldfinger SE, Fletcher SW. Academia industry collaboration in continuing medical education: Description of two approaches. J Contin Educ Health Prof 2002; 22(1) 43-54.
97. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 1988; 8(1): 13-20.
98. CMA policy summary. Physicians and the pharmaceutical industry. CMAJ 1994; 256.
99. Lexchin J, Cassels A. Does the C in CME stand for “continuing” or “commercial”? CMAJ, 2005; 172(2) 160-2.
100. Stahl S. It takes two to entangle: Separating medical education from pharmaceutical promotion. Psychopharmacology Educational Update. 2005 (March):1, 6
101. American Medical Association Council on Ethical and Judicial Affairs. Opinion 8.061: Gifts to -physicians from industry. Available at: http://www.ama-assn.org/ama/pub/category/4001.html (last accessed June 2006)
102. Principles to guide the relationship between graduate medical education and industry. Available at: http://www.acgme.org (under GME information; under position papers) (last accessed June 2006). ACGME, 2002
103. http://www.accme.org “Ask ACCME” http://www.accme.org/index.cfm/fa/faq.home/Faq.cfm Refer to the six standards of commercial support. Last accessed 12/2006
104. AAMC Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress: Policy and guidelines for the oversight of individual financial interests in human subjects research. Association ofAmerican Medical Colleges, 2001. Available at: www.aamc.org/research/coi/start.htm (last accessed June 2006)
105. AAMC Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress II: Principles and recommendations for oversight of an institution's financial interests in human subjects research. Association of American Medical Colleges, 2002. Available at: www.aamc.org/research/coi/start.htm (last accessed June 2006)
106. Coyle SL., Physician-industry relations, part 1: Individual physicians. Ann Intern Med 2002; 136(5):396-402
107. Coyle SL. Physician-industry relations, part 2: Organizational issues. Ann Intern Med 2002; 136(5) 403-6
108. CMA Policy Summary. Physicians and the pharmaceutical industry. CMAJ 1994; 150:256 A-C. Available at: http://www.cma.ca (under pol-icy/advocacy; under CMA policy base) (last accessed June 2006).
109. Whal DS, American Psychiatric Association Ethics Committee. Ethics Primer of the American Psychiatric Association. APA, 2001.
110. American College of Obstetricians and Gynecologists. Guidelines for relationships with industry. Obstet Gynecol 2001; 98(4) 703-6.
111. Tsai AC. Policies to regulate gifts to physicians from industry. JAMA2003; 290:1776
112. Wager E. How to dance with porcupines: Rules and guidelines on doctors’ relations with drug companies. BMJ 2003 Aug; 327(7410) 341.
113. Code for interactions with health care professionals http://www.phrma.org/code_on_interactions_with_healthcare_professionals/Last accessed 12/2006.
114. American Academy of Pharmaceutical Physicians. Code of ethics. Available at: www.aapp.org/ethics.php (last accessed June 2006).
115. Office of Inspector General. Compliance Program Guidance for Pharmaceutical Manufacturers. Available at: www.oig.hhs.gov/fraud/complianceguidance.html (last accessed June 2006)
116. American Medical Association. Interactions with pharmaceutical industry representatives. Available at: http://www.ama-assn.org/ama/pub/category/11910.html (last accessed June 2006)
117. Mohl PC. Psychiatric training program engagement with the pharmaceutical industry: An educational issue, not strictly an ethical one. Acad Psychiatry 2005; 29(2) 215-21.
118. Blake RL Jr., Early EK. Patients’ attitudes about gifts to physicians from pharmaceutical companies. J Am Board Fam Pract 1995; 8(6) 457-64.
119. Gibbons, RV, Landry FJ, Blouch DL, Jones DL, Williams FK, Lucey CR, Kroenke K. A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998; 13(3): 151-4
120. Wolf BL. Drug samples: Benefit or bait? JAMA 1998; 279(21): 1698-9
121. Shaughnessy AF, Bucci KK. Drug samples and family practice residents. Ann Pharmacother 1997; 31(11):1296-300.
122. Groves KE, Sketris I, Tett SE. Prescription drug samples - does this marketing strategy counteract policies for quality use of medications? J Clin Pharm Ther 2003; 28(4) 259-71
123. Chew LD, O’ Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physicians survey of the effect of drug sample availability on physicians’ behavior. J Gen Intern Med 2000; 15(7) 478-83
124. Westfall JM, McCabe J, Nicholas RA. Personal use of drug samples by physician and office staff. JAMA 1997; 278(2): 141-3
125. Storrs FJ. Drug samples: A conflict of interest? Arch Dermatol 1988; 124(8) 283-5
126. Morelli D, Koenigsberg MR. Sample medication dispensing in a residency practice. J Fam Pract 1992; 34(1) 42-8
127. Westfall JM, McCabe J, Nicholas RA. Personal use of drug samples by physicians and office staff, author reply. JAMA 1997; 278(19): 1568-9
128. O’ Young T, Hazlet TK. Removal of drug samples from two teaching institutions. Am J Health Syst Pharm 2000; 57(12) 179-80.
129. Mehta HJ. Personal use of drug samples by physicians and office staff. JAMA 1997; 278(19)1568
130. Backer E.I., Lebsack JA, Van Tonder RJ, Crabtree BF. The value of pharmaceutical representative visits and medication samples in community-based family practices. J Fam Pract 2000; 49(9) 811-16.
131. Lurk JT, DeJong DJ, Woods TM, Knell ME, Carroll CA. Effect of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety net-provider setting. Am J Health Syst Pharm 2004; 61(3):267-72
132. Haxby DG, Rodriguez GS, Zechnich AD, Schuff RA, Tanigawa JS. Manufacturers’ distribution of drug samples to a family medicine clinic. Am J Health Syst Pharm 1995; 52(5) 496-9
133. Weiner S, Dischler J, Horvitz C. Beyond pharmaceutical manufacturer assistance: Broadening the scope of an indigent drug program. Am J Health Syst Pharm 2001; 58(2) 46-50
134. Paj MP, Gracie DM., Bertino JS Jr. Waste generation of drug product samples versus prescriptions obtained through pharmacy dispensing. Pharmacotherapy 2000; 20(5) 593-5
135. Tong KL, Lien CY. Do pharmaceutical representatives misuse their drug samples? Can Fam Physician 1995; 41:1363-6.
136. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000; 283(3) 373-80
137. Shapiro D. Drug companies get too close for medical school's comfort. http://query.nytimes.com/gst/fullpage.html?res=9FooE2D81439F933A15752CoA9629C8B63&sec=health&pagewanted=2 Last accessed 12/2006
138. Relman AS. Your doctor's drug problem. http://www.dearshrink.com/nytimes_docsdrugprobi118o3.pdf. Last accessed 12/2006.
139. Wadman M. Spitzer sues drug giant for deceiving doctors. Nature 2004; 429(10) 589
140. Harris G. Pfizer to pay $420 million in illegal marketing case. The New York Times. May 14, 2004. Page C6
141. Kowalcyzk L. Pfizer unit agrees to $430 million in fines. Boston Globe. May 14, 2001. Page D1
142. Yamey G. Eli Lilly violates patients’ privacy. BMJ 2001; 323(7304) 65.
143. Harris G. Drug makers are still giving gifts to doctors, FDA officials tell senators. The New York Times. March 4, 2005. Page A15.
144. Hensley S, Martinez B. To sell their drugs, companies increasingly rely on doctors. Wall Street Journal. July 15, 2005. Pages A1, A2 Beatty Y. Gifts from pharmaceutical representatives: Exercise caution. Tenn Med 2005; 981 (1):33-4
145. Robinson DJ. Interactions between drug reps and physicians. Physicians News Digest 2004 (April): 1-3
146. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians’ relationships with the pharmaceutical industry - self regulation in the shadow of federal prosecution. N Engl J Med 2004; 351 (18): 1891-900
147. Tsai AC. Policies to regulate gifts to physicians from the industry. JAMA 2003; 290(13):1776
148. Litman M, Sheremeta L. The report of the Committee of Inquiry on the case involving Dr. Nancy Olivieri: A fiduciary law perspective. Health Law Rev 2002; 10(2) 3-13
149. Huang AJ. The rise of direct to consumer advertising of prescription drugs in the United States. MSJAMA 2000; 284(17):2240.
150. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P. Influence of patients’ requests for direct to consumer advertised antidepressants. A randomized controlled trial. JAMA 2005; 293(16) 1995-2002
151. Hollon MF. Direct to consumer advertising: A haphazard approach to health promotion. JAMA 2005; 293(16) 2030-3
152. Henney JE. Challenges in regulating direct to consumer advertising. JAMA 2000; 284(17):2242
153. Kravitz RL. Direct to consumer advertising of prescription drugs: Implications for the patient-physician relationship. MSJAMA 2000; 284(17)2244
154. Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA. Influence of direct to consumer pharmaceutical advertising and patients’ requests on prescribing decisions: 2 site cross sectional survey. BMJ 2002; 324(7332):278-9.
155. IMS Health. Jan 2000-Dec 2000. Prescription drug trends. Fact Sheet 3057-03. Kaiser Family Foundation, Menlo Park, CA, 2004.
156. Bonaccorso, S.N, Sturchio JL. For and against: Direct to consumer advertising is medicalizing normal human experience: Against. BMJ2002; 324(7342) 910-11
157. Lenhardt E. Why so glum? Toward a fair balance of competitive interests in direct to consumer advertising and the well being of the mentally ill consumers it targets. Health Matrix Cleveland 2005; 15(1): 165-204.
158. Robinson AR, Hohmann KB, Rifkin J, Topp D, Gilroy CM, Pickard JA, Anderson RJ. Direct to consumer pharmaceutical advertising. Arch Intern Med 2004; 164(4) 427-32.
159. Murray E, Lo B, Pollack L, Donelar K, Lee K. Direct-to-consumer advertising: Physician views of its effects on quality of care and the doctor-patient relationship. J Am Board Fam Pract 2003; 16(6) 513-24.
160. Chin MH. The patient's role in choice of medications: Direct to consumer advertising and patient decision aids. Yale J Health Policy Law Ethics 2005; 5(2):771-84
161. Freudenheim M. Psychiatric drugs are now promoted directly to patients. http://query.nytimes.com/gst/fullpage.html?sec=health&res=9503E6D8163FF934A25751C0A96E958260 Last accessed 12/2006.
162. Mintzes B. For and against: Direct to consumer advertising is medicalizing normal human experience: For. BMJ 2002; 324(7342): 908-9
163. Maubach N, Hoek J. New Zealand general practitioners’ views on direct-to-consumer advertising of prescription medicines: A qualitative analysis. N Z Med J 2005; 118(1215): 1543
164. Wager E. How to dance with porcupines: Rules and guidelines on doctors’ relations with drug companies. BMJ 2003; 326(7400): 1196-8.
165. Kmietowicz Z. WMA sets rules on how doctors handle industry sponsorship. BMJ 2004; 329(747):876
166. Aasland OG, Forde R. Physicians and drug industry: Attitudes and practice. Tidiskrift for Den Norske Laegeforening 2004; 124(20): 2603-6
167. Haug C. Dangerously tempting fellowships. Tidiskrift for Den Norske Laegeforening 2004; 124(20)2597
168. Zimmerman R, Romanowski M, Malach P. The legal evaluation of contacts between a physician and a pharmacological company. Klin Oczna 2004; 106(6):809-11
169. Haser I, Hofmann A. New conduct recommendations for physicians cooperating with the pharmaceutical industry? The “FS Codex” and its consequences for physicians. Anaesthesist 2005; 54(3) 263-7
170. Helmchen H. Psychiatrists and the pharmaceutical industry. Nervenarzt 2003; 74(11):955-64
171. Komesaroff PA. Ethical issues in the relationships with industry: An ongoing challenge. J Pediatr Child Health 2005; 41(11) 558-60.
172. Komesaroff PA, Kerridge IH. Ethical issues concerning the relationships between medical practitioners and the pharmaceutical industry. Med J Aust 2002; 176(3): 118-21
173. Estevez De Vidts A. Physicians and the hospitality of pharmaceutical companies. Rev Med Chil 2004; 132(4) 522
174. Malavige GN. Doctors, drug companies and medical ethics: A Sri Lankan perspective. Indian J Med Ethics 2004; 1(1):26.
175. Tengilimoglu D, Kisa A, Ekiyor A. The pharmaceutical sales rep/physician relationship in Turkey: Ethical issues in an international context. Health Mark Q 2004; 22(1):21-39
176. Herxheimer A. Relationships between the pharmaceutical industry and patients organization. BMJ 2003; 326(7400): 1208-10.
177. Burton B, Rowell A. An unhealthy spin. BMJ 2003; 326(7400): 1205-7.
178. Hirst J. Charities and patient groups should declare interests. BMJ2003; 326(7400): 1211
179. Benko LB. Managed care gets a closer look from feds. Mod Health 2002; 32(21): 10-11
180. Zoutman DE, Ford BD, Bassili AR. The confidentiality of patient and physician information in pharmacy prescription records. CMAJ 2004; 170(5) 815-16
181. Pearson LJ, Can prescriber profiling happen to you?Nurse Pract 2003; 28(12):8
182. Stokamer CL. Pharmaceutical gift giving: Analysis of an ethical dilemma. J Nurs Adm 2003; 33(1):48-51